TORL Bio's Ixo-V Delivers Promising Results in Recurrent Ovarian Cancer

LOS ANGELES, CA – June 18, 2026 – In the relentless battle against recurrent ovarian cancer, a formidable foe with historically bleak prognoses, a new glimmer of hope has emerged. Clinical-stage biotechnology company TORL BioTherapeutics today unveiled encouraging preliminary data for its targeted therapy, ixotatug vedotin (Ixo-V), showing significant anti-tumor activity when combined with an existing standard of care.

Presented at the prestigious European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress 2026, the Phase 1 data reveals that the combination of Ixo-V and bevacizumab achieved an objective response rate (ORR) of 32.1% across 29 participants with recurrent ovarian cancer. Even more impressively, the disease control rate (DCR)—which includes patients whose tumors shrank or remained stable—reached 92.9%. These figures stand in stark contrast to the low single-digit response rates often seen with conventional chemotherapies in this heavily pre-treated patient population.

A New Strategy for a Persistent Challenge

Ovarian cancer is the most lethal gynecologic malignancy, largely because it is often managed as a chronic disease following recurrence. Up to 75% of patients with advanced disease will see their cancer return. A critical distinction is made for patients with platinum-resistant ovarian cancer (PROC), whose disease recurs within six months of completing platinum-based chemotherapy. This group faces particularly grim outcomes, with traditional non-platinum chemotherapies offering response rates typically below 12% and progression-free survival measured in mere months.

The data from TORL's ongoing study suggests a meaningful path forward. The 32.1% ORR represents a significant improvement over historical benchmarks. The combination therapy also demonstrated a manageable safety profile, with no reports of clinically significant bleeding, ocular events, or bowel perforations—critical considerations for patients who have already endured multiple rounds of taxing treatments.

"We are encouraged by the emerging safety and efficacy profile of Ixo-V in combination with bevacizumab in patients with CLDN6-positive recurrent ovarian cancer, a population with particularly poor prognosis and high unmet need," said Aran Maree, M.D., Chief Executive Officer of TORL BioTherapeutics. He noted that the results provide important clinical support for using Ixo-V with existing standards of care and in earlier lines of therapy.

Crucially, the study included patients who had already been treated with a gauntlet of modern therapies, including PARP inhibitors, bevacizumab, and even another antibody-drug conjugate, mirvetuximab soravtansine. The fact that Ixo-V still elicited responses in these patients underscores its potential to fill a critical gap for those who have exhausted other options.

The Science Behind the Target: Unlocking Claudin 6

At the heart of this new approach is a highly specific molecular target: Claudin 6 (CLDN6). CLDN6 is a transmembrane protein that is highly expressed on the surface of several cancer types, including about half of all ovarian cancers, but is largely absent from healthy adult tissues. This differential expression makes it an almost perfect target for precision oncology, allowing a therapy to attack cancer cells while sparing healthy ones.

Ixotatug vedotin is an antibody-drug conjugate (ADC), a class of drugs often described as “biological missiles.” It consists of a monoclonal antibody designed to seek out and bind to the CLDN6 protein on cancer cells. Once attached, the ADC is internalized by the cell, where it releases a potent cytotoxic payload, killing the cancer cell from within. This targeted delivery mechanism aims to maximize efficacy while minimizing the systemic side effects associated with traditional chemotherapy.

The intense scientific interest in CLDN6 is not limited to TORL. The protein is the focus of a burgeoning field of research, with other companies developing different modalities to attack it, including T-cell engagers and advanced CAR T-cell therapies. This broader industry pursuit validates the importance of CLDN6 as a high-value target and places TORL's ADC at the forefront of a major new wave in cancer treatment.

TORL's Strategic Blueprint and the Road Ahead

For TORL BioTherapeutics, these results represent a major validation of its core strategy. The company, which operates through a strategic partnership with the world-renowned Slamon Research Lab at UCLA, is focused on developing a pipeline of novel ADCs and antibodies against promising cancer targets. The positive data for Ixo-V, which has already received Fast Track Designation from the U.S. Food and Drug Administration, solidifies its position as the company's lead asset.

The path forward is clearly defined. TORL is actively enrolling patients in CATALINA-2, a global, pivotal Phase 2 study evaluating Ixo-V as a monotherapy in women with CLDN6-positive, platinum-resistant ovarian cancer. The topline results from this registrational trial, anticipated in mid-2027, will be a critical inflection point for both the drug and the company.

In parallel, the company is exploring Ixo-V's potential in other settings. The CATALINA-4 study is investigating the drug in combination with chemotherapy before initial surgery for advanced ovarian cancer, and its application is also being evaluated in other CLDN6-positive malignancies like non-small cell lung cancer.

Navigating a Crowded and Evolving Market

The treatment landscape for recurrent ovarian cancer is complex and rapidly evolving. While Ixo-V's early results are promising, it will enter a market with established targeted therapies, including PARP inhibitors and bevacizumab. Another ADC, mirvetuximab soravtansine (Elahere), gained FDA approval in 2022 for patients with FR-alpha-positive PROC, demonstrating the viability of ADCs in this space.

However, Ixo-V's distinct target, CLDN6, provides a key differentiator. It offers a solution for a different biomarker-defined patient population, potentially complementing rather than directly competing with FR-alpha-targeted agents. The preliminary data showing activity in a patient who had previously received mirvetuximab soravtansine further supports its potential role as a sequential therapy. As the field of oncology moves ever deeper into personalized, biomarker-driven medicine, having a robust and effective option for the significant CLDN6-positive patient population could secure TORL a vital and valuable position in the future of cancer care.